Catalyst Pharmaceuticals, Inc. (CPRX)
| Market Cap | 590.21M |
| Revenue (ttm) | 120.14M |
| Net Income (ttm) | 72.22M |
| Shares Out | 103.81M |
| EPS (ttm) | 0.68 |
| PE Ratio | 8.49 |
| Forward PE | 15.92 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 22 |
| Last Price | $5.77 |
| Previous Close | $5.80 |
| Change ($) | -0.03 |
| Change (%) | -0.52% |
| Day's Open | 5.79 |
| Day's Range | 5.68 - 5.80 |
| Day's Volume | 491,209 |
| 52-Week Range | 2.88 - 5.90 |
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
- Without an NOC, Ruzurgi ® is without a Marketing Authorization in Canada
CORAL GABLES, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, devel...
Catalyst's (CPRX) earnings beat estimates in the first quarter of 2021 while revenues missed the same.
Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
-Firdapse® Q1 2021 Net Revenues of $30.2 Million
Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.
Catalyst is facing its fair share of classic pharma challenges.
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CORAL GABLES, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, deve...
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
With solid revenue growth, these stocks have the potential to more than triple over the next few years.
CORAL GABLES, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing inn...
To increase one's chances of beating the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.
Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.
Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and 3.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- Firdapse® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CORAL GABLES, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing in...
CORAL GABLES, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing inn...
Now that AMC, GameStop, American Airlines and Bed, Bath & Beyond have been pushed to wild levels, well above any sane valuation, the question is which companies will be the next to be “recommended” by m...
Investors can start the new year off right by digging into these three small but fiery stocks.
Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.
Investors focused on assets with high returns may want to consider the following non-cyclical stocks, as their earnings yields (as calculated through Joel Greenblatt's method) are outperforming the S&P ...
CORAL GABLES, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing inn...
Catalyst Pharma is a commercial-stage small biotech with a highly profitable orphan drug Firdapse for adult LEMS patients in the US market. Catalyst Pharma is trading at PE ratio of 5 and price-to-sales...
Three referenced quant rating categories (value, growth, and profitability) are significant considerations in selecting healthcare investments. The data underlying the value, growth, and profitability t...
Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2020 Results - Earnings Call Transcript
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.
Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.10%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
- Firdapse® Third Quarter Net Revenues of $ 29. 2 Million
Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.
Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk. The post Despite Legal Drama, Catalyst Pharmaceuticals Looks ...
CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing inn...
As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBIT), Cataly...
Typically, a major clinical victory would boost names like Catalyst Pharmaceuticals stock. Unfortunately, some political rumblings and an unexpected competitor got in the way of CPRX.
CORAL GABLES, Fla., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing inn...
Catalyst Pharmaceuticals Has Potential To Push Higher If They Can Overcome Current Headwinds
Issued Patent is the First Covering Firdapse® Issued Patent is the First Covering Firdapse®
CORAL GABLES, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst's case against the FDA has adop...
Investors often get excited about small-cap biotech and emerging pharmaceutical stocks because the upside can be exponential if their drugs and treatments become a hit.
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst can't seem to catch a break in the clinic these days.
Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of concern.
Notice of Application for Judicial Review Filed Today in the Federal Court of Canada Notice of Application for Judicial Review Filed Today in the Federal Court of Canada
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthe... [Read more...]
| Industry Biotechnology | IPO Date Nov 8, 2006 |
| CEO Patrick McEnany | Employees 74 |
| Stock Exchange NASDAQ | Ticker Symbol CPRX |
Financial Performance
In 2020, CPRX's revenue was $119.07 million, an increase of 16.39% compared to the previous year's $102.31 million. Earnings were $74.98 million, an increase of 135.24%.
Analyst Forecasts
According to 5 analysts, the average rating for CPRX stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 29.98% from the latest price.